BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
The Reduced Portage Horse: An Inheritance Reconsidered for Present day Experience - 2Traveling Alone: An Excursion of Self-Disclosure
- 3Voting begins in Uganda’s presidential election during internet shutdown and polling station delays
- 4Audits of 6 Specialty Mixed drinks
- 5Soldiers seize power in Guinea-Bissau and detain the president
- A Texas GOP congressman is retiring. Trump just endorsed his identical twin to replace him.
- Horses really can smell our fear, new study finds
- Fundamental Home Items Each Animal person Needs
- 'Euphoria' releases Season 3 photos with Zendaya, Sydney Sweeney, Jacob Elordi and others: See them
- The Best Web-based Courses for Ability Advancement
- The 10 Most Significant Virtual Entertainment Missions
- These Cities Led Global Jet-Setting In 2025, According To New Data
- Manual for 6 well known Amusement Park
- Top 10 Smash hit Computer games of the Year
